Wednesday, May 25, 2022 2:47:47 PM
Meanwhile, do you remember Christopher Moreau (CEO) telling the market back in Q4 how EXCITING it was going to be for Algernon Pharmaceuticals in 2022?
It would appear that dredging up old stories suggests one isn't very excited at all. It's gotta be killing Moreau to not be in front of a lens spinning and spewing more stories.
The following web address + email address would be money well spent, but like everything else Moreau does, it'll likely be something management/shareholders will learn the hard way:
https://algernonpharma.com/
After all, all the so-called marketing has been Algernon's biggest quarterly expense. Anybody think they've gotten their monies worth to date?
Expect more of the same...
M$
P.S Anyone seen or heard from the BioPub Boys lately? I'm not a subscriber so I'm curious to know if they're still receiving private updates by the CEO & Company? Maybe it doesn't matter since Dr. KSS remains an insiders advisor (conflict of interest) @ Algernon Pharmaceuticals Inc.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM